MarkJosephBuchfuhrerMD
Pulmonology • Downey, CAPleural Disease, Sleep Medicine
Consulting Assistant Professor, Stanford University School of Medicine
Dr. Buchfuhrer is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
11480 Brookshire Avenue
# 108
Downey, CA 90241Phone+1 562-904-1101Fax+1 562-904-1105
Education & Training
Los Angeles County-Harbor-UCLA Medical CenterInternship, Transitional Year, 1980 - 1981
University of Ottawa Faculty of MedicineClass of 1977
Certifications & Licensure
CA State Medical License 1979 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Pulmonary Disease
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification eClinicalWorks EHR, eClinicalWorks LLC, 2011-2013
Clinical Trials
- A Post-Market Study for Long-Term Effectiveness and Safety of the NTX100 for RLS Start of enrollment: 2023 Nov 15
Roles: Contact
Publications & Presentations
PubMed
- 59 citationsThe Management of Restless Legs Syndrome: An Updated Algorithm.Michael H. Silber, Mark J. Buchfuhrer, Christopher J. Earley, Brian B. Koo, Mauro Manconi
Mayo Clinic Proceedings. 2021-07-01 - 173 citationsGuidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of...Diego Garcia-Borreguero, Michael H. Silber, John W. Winkelman, Birgit Högl, Jacquelyn L. Bainbridge
Sleep Medicine. 2016-05-01 - 15 citationsRestless legs syndrome (RLS) with expansion of symptoms to the face.Mark J. Buchfuhrer
Sleep Medicine. 2008-01-01
Press Mentions
AASM’s New RLS Guidelines Recommend Peroneal Nerve Stimulation TherapyOctober 8th, 2024- Noctrix Health Secures $40 Million Series C Financing to Commercialize Novel Device Treatment for Restless Legs Syndrome (Rls)August 19th, 2024
- Noctrix Health Announces Enrollment of First Patient in the RESTFUL Study and Publication of Positive Pilot Study ResultsMay 25th, 2021
- Join now to see all
Professional Memberships
- Fellow
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
